J. Bolodeoku, T. Gbaa, K. Morris, and S. Whitehead, “Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic”, BJHMR, vol. 10, no. 6, pp. 91–102, Dec. 2023.